Gene Expression Profiling of Renal Medullary Carcinoma: Potential Clinical Relevance

Cancer

Volumn 100, Issue 5, 2004, Pages 976-985

  Yang, Ximing J ^a,b   Sugimura, Jun ^c   Tretiakova, Maria S ^a   Furge, Kyle ^c   Zagaja, Gregory ^a   Sokoloff, Mitchell ^a   Pins, Michael ^b   Bergan, Raymond ^b   Grignon, David J ^d   Stadler, Walter M ^a   Vogelzang, Nicholas J ^a   Teh, Bin Tean ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Medullary carcinoma; Microarray; Molecular biology; Renal carcinoma; Sickle cell

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; CAPECITABINE; COMPLEMENTARY DNA; GEMCITABINE; PROTEIN;

ADULT; ARTICLE; CANCER CLASSIFICATION; CASE REPORT; CHROMOSOME ABERRATION; DNA MICROARRAY; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY MEDULLA; KIDNEY MEDULLARY CARCINOMA; MALE; MOLECULAR BIOLOGY; MOLECULAR CLONING; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SICKLE CELL TRAIT; TRANSITIONAL CELL CARCINOMA; UNINDEXED SEQUENCE;

ADULT; BIOPSY, NEEDLE; CARCINOMA, MEDULLARY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM STAGING; NEPHRECTOMY;

EID: 10744231407     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20049     Document Type: Article

References (38)

1. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet. 1998;352: 1691-1696.
2. Mostfi FK, Davis C Jr. World Health Organization international histological classification of tumours. Springer: Berlin, 1998.
3. Avery RA, Harris JE, Davis CJ Jr., Borgaonkar DS, Byrd JC, Weiss RB. Renal medullary carcinoma: clinical and therapeutic aspects of a newly described tumor. Cancer. 1996;78: 128-132.
4. Adsay NV, deRoux SJ, Sakr W, Grignon D. Cancer as a marker of genetic medical disease: an unusual case of medullary carcinoma of the kidney. Am J Surg Pathol. 1998;22: 260-264.
5. Davis CJ Jr., Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol. 1995;19:1-11.
6. Desai S, Kulkarni JN. Re: renal medullary carcinoma. J Urol. 1999;161:1581.
7. Pirich LM, Chou P, Walterhouse DO. Prolonged survival of a patient with sickle cell trait and metastatic renal medullary carcinoma. J Pediatr Hematol Oncol. 1999;21:67-69.
8. Stahlschmidt J, Cullinane C, Roberts P, Picton SV. Renal medullary carcinoma: prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement. Med Pediatr Oncol. 1999; 33:551-557.
9. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376-2381.
10. Swartz MA, Karth J, Schneider DT, Rodriguez R, Beckwith JB, Perlman EJ. Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology. 2002;60:1083-1089.
11. Takahashi M, Sugimura J, Yang XJ, et al. Molecular subclassification of kidney cancer and the discovery of new diagnostic markers. Oncogene. 2003;22:6810-6818.
12. Boer JM, Huber WK, Sultmann H, et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 2001;11:1861-1870.
13. Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001;158:1639-1651.
14. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol. 2003;162:925-932.
15. Takahashi M, Yang XJ, Lavery TT, et al. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Res. 2002;62:6598-6605.
16. Sobin LH, Wittekind C, editors. International Union Against Cancer. TNM classification of malignant tumors. 5th edition. New York: John Wiley & Sons, 1997.
17. Tran TT, Sengupta E, Yang XJ. Prostatic foamy gland carcinoma with aggressive behavior: clinicopathologic, immunohistochemical, and ultrastructural analysis. Am J Surg Pathol. 2001;25:618-623.
18. Hegde P, Qi R, Abernathy K, et al. A concise guide to cDNA microarray analysis. Biotechniques. 2000;29:548-550, 552-554, 556 passim.
19. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol. 1999;303:179-205.
20. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863-14868.
21. Rhodes DR, Miller JC, Haab BB, Furge KA. CIT: identification of differentially expressed clusters of genes from microarray data. Bioinformatics. 2002;18:205-206.
22. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344: 539-548.
23. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002;30:e15.
24. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5:299-314.
25. Clamp M, Andrews D, Barker D, et al. Ensembl 2002: accommodating comparative genomics. Nucleic Acids Res. 2003;31:38-42.
26. Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol. 2002;26:921-925.
27. Kovacs G. Molecular cytogenetics of renal cell tumors. Adv Cancer Res. 1993;62:89-124.
28. Bugert P, Kovacs G. Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol. 1996;149:2081-2088.
29. Le Jan S, Amy C, Cazes A, et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol. 2003;162:1521-1528.
30. Robertson DM, Stephenson T, Pruysers E, et al. Inhibins/activins as diagnostic markers for ovarian cancer. Mol Cell Endocrinol. 2002;191:97-103.
31. Srigley JR, Eble JN. Collecting duct carcinoma of kidney. Semin Diagn Pathol. 1998;15:54-67.
32. Droz D, Patey N, Paraf F, Chretien Y, Gogusev J. Composition of extracellular matrix and distribution of cell adhesion molecules in renal cell tumors. Lab Invest. 1994;71:710-718.
33. Koshikawa N, Moriyama K, Takamura H, et al. Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. Cancer Res. 1999;59:5596-5601.
34. Greene LM, Twal WO, Duffy MJ, et al. Elevated expression and altered processing of fibulin-1 protein in human breast cancer. Br J Cancer. 2003;88:871-878.
35. Brenner W, Gross S, Steinbach F, Horn S, Hohenfellner R, Thuroff JW. Differential inhibition of renal cancer cell invasion mediated by fibronectin, collagen IV and laminin. Cancer Lett. 2000;155:199-205.
36. Seftor RE, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 2001;61:6322-6327.
37. Takahashi M, Sugimura J, Yang XJ, et al. Gene expression profiling of renal cell carcinoma and its implications in diagnosis, prognosis, and therapeutics. Adv Cancer Res. 2003;89:157-181.
38. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40:403-439.